GB-115 vs Adamax
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester
GB-115 is a synthetic dipeptide anxiolytic developed in Russia, chemically the amide of N-phenylhexanoyl-glycyl-L-tryptophan and described as a retro-analogue of cholecystokinin-4. Rather than acting like a benzodiazepine, it blocks cholecystokinin receptors, a different anti-anxiety route. It has been studied in animals and in a small pilot human study, but it is not an approved or widely available medication.
Also: Semax derivative
Adamax is sold widely as an enhanced Semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. Vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. This page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- GB-115 has stronger research evidence (Human Trials) compared to Adamax (Preclinical).
Detailed Comparison
| Attribute | GB-115 | Adamax |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Cholecystokinin (CCK) is a peptide that acts as a neurotransmitter in the brain, and activating its CCK-2 (also called CCK-B) and CCK-1 receptors tends to trigger anxiety and panic-like states. GB-115 works as an antagonist at these cholecystokinin receptors, meaning it occupies the receptor and blocks CCK from setting off that anxiety signaling. In animal work it specifically prevented anxiety provoked by CCK-4, which shares a pharmacological target with GB-115. This CCK-blocking mechanism is the proposed explanation for its calming effect, and it is distinct from the GABA system that classic sedatives act on. | What is claimed is that Adamax is a structurally modified Semax analog, with modifications intended to improve stability and blood-brain barrier penetration relative to Semax itself. Semax is a synthetic fragment of ACTH (4-10) developed in Russia, and its best-supported mechanism is upregulation of BDNF and NGF in the hippocampus and cortex, alongside modulation of the monoamine systems and some effect on the melanocortin pathway. If Adamax is what it is sold as, its mechanism should be broadly that of Semax with altered pharmacokinetics. That is a reasonable inference and it is not the same thing as a demonstrated mechanism. No published pharmacology characterises Adamax specifically. |
| Common Dosing | 6 mg daily (2 mg three times daily) 2-3 times daily (morning, afternoon, evening) | 100-300 mcg daily (intranasal) Once daily, morning |
| Administration | Oral tablets or sublingual | Intranasal is the most commonly reported route, following Semax practice. Subcutaneous is also reported. |
| Typical Duration | 21+ days in clinical trials, effects noted by day 7 | Community protocols typically report 2-4 week blocks rather than continuous use |
| Best Time to Take | Morning and throughout the day | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The research record is real but thin and almost entirely from a single Russian group. In rodent studies (rats, BALB/c and C57Bl/6 mice), GB-115 reduced anxiety induced by CCK-4 and by yohimbine, with effects that varied by mouse strain, and it stayed effective after long-term dosing without producing tolerance or a withdrawal syndrome when stopped. Preclinical safety work has also been published. The only human data comes from a small pilot clinical study of 25 patients with generalized anxiety disorder given 6 mg daily for 21 days, where anxiety scores on the Hamilton scale fell substantially and fatigue scores improved. Importantly, that study was a single-arm pilot with no placebo or control group, so it cannot prove the drug caused the improvement. There are no large randomized controlled trials, no Western regulatory approval, and the evidence base remains preliminary. | There is no peer-reviewed clinical or preclinical literature on Adamax under that name that stands up to a search. What exists is a substantial Russian-language research base on Semax, its parent, which includes clinical use in Russia for stroke recovery, cognitive impairment and optic nerve conditions, and which supports the BDNF and NGF mechanism. Extending that evidence to Adamax requires assuming the analog behaves like the parent, and no published work confirms that assumption. Everything circulating about Adamax's potency relative to Semax is vendor claim and user report, not measurement. The honest position is that this is an uncharacterized research compound whose parent has real but largely non-Western evidence behind it. If you want the compound with actual literature, that compound is Semax. |
Frequently Asked Questions: GB-115 vs Adamax
What is the difference between GB-115 and Adamax?
GB-115 is a cognitive peptide that gb-115 is a synthetic dipeptide anxiolytic developed in russia, chemically the amide of n-phenylhexanoyl-glycyl-l-tryptophan and described as a retro-analogue of cholecystokinin-4. rather than acting like a benzodiazepine, it blocks cholecystokinin receptors, a different anti-anxiety route. it has been studied in animals and in a small pilot human study, but it is not an approved or widely available medication. Adamax is a cognitive peptide that adamax is sold widely as an enhanced semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. this page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GB-115 or Adamax?
Neither is universally "better" - the choice depends on your specific goals. GB-115 is typically used for cognitive purposes, while Adamax is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GB-115 and Adamax be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GB-115 and Adamax together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.